tbuckley/cabot-search huggingface dataset:
PTH-055 ABO Blood Group-Specific Immunoglobulins in Crohn’s Disease
Authors: CW-T Ting, S Hussain, S Wurie, N O’Connell, R Higgins, D Briggs, N Krishnan, R Arasaradnam, S Daga
Journal: Gut (2016)

<h3>Introduction</h3> The pathogenesis of Crohn’s disease (CD) is complex and believed to be interplayed by genetic susceptibility, enteric microflora and tissue injury mediated by abnormal immune response. Several studies have described the association between ABO blood group, enteric microflora composition and predisposition to gastrointestinal (GI) infections. The mucosal layer of the GI tract forms the first layer of immune defenses with mucus abundant in secretory immunoglobulins, and studies have shown that non-O blood group and FUT2-determined ABO antigen non-secretor were linked to more severe CD. It was suggested that ABO antibodies are induced via an enteric route by cross-reactivity from microflora-derived molecules . However, little is known about the role of ABO antibodies in the context of CD. Therefore we assessed whether blood group-specific antibodies are implicated in CD pathogenesis. <h3>Methods</h3> We compared the immunoglobulin class profile of blood group-specific antibodies in blood group A, B and O individuals. Plasma samples were collected from CD cohort (n = 45, recruited from the FaMIsHED study) with age- and gender-matched healthy donors (n = 89 data from service development study). Medications of CD cohort include none (n = 15), 5 ASA (n = 21), immunosuppressant (n = 12) and biologics (n = 10). A1rr and Brr cells were used, anti-A1 and anti-B IgG, IgA and IgM levels were measured by Relative Median Fluorescence using flow cytometry. Mann-Whitney U test was used to assess statistical significance of different antibody levels between CD and healthy cohorts. <h3>Results</h3> Blood group O CD patients (n = 20) have significantly lower anti-A1 IgG, IgA and IgM compared to the healthy blood group O cohort with p value of 0.0001, 0.0009 and &lt;0.0001 respectively; but only anti-B IgM was significantly lower (p = 0.005) in the CD patients compared to controls and no significant difference was observed in IgG (p = 0.5197) and IgA (p = 0.626). Blood group A CD patients (n = 19) was found to have lower anti-B IgG response (p = 0.041) and no significant difference was found in anti-B IgA (p = 0.2748) and IgM (p = 0.2012) levels. Blood group B CD patients (n = 6) were found to have lower anti-A1 IgA (p = 0.0131) compared to healthy controls but no significant difference was observed in IgG (p = 0.101) and IgM (p = 0.174). <h3>Conclusion</h3> CD patients were found to have lower than baseline ABO antibodies. However, it is not known whether these findings represent the cause or effect of disturbed immune modulations, or their roles in modulating intestinal microflora. Further research into the difference in ABO antibodies class profile in a larger cohort, and comparison of ABO antibodies class profile of CD patients in remission and relapse are required. <h3>Disclosure of Interest</h3> None Declared
First-in-Human Phase 1 Dose Escalation Study of NPI-0052, a Novel Proteasome Inhibitor, in Patients with Lymphoma and Solid Tumor
Authors: Paul A. Hamlin, Carol Aghajanian, David Hong, Anas Younes, Michael A. Palladino, Angie M. Longenecker, Gillian Cropp, G. Kenneth Lloyd, Alison L. Hannah, Matthew A. Spear, Razelle Kurzrock
Journal: Blood (2008)
The Influence of Hemostasis Genetic Features on Thrombosis Rates in Patients with Polycythemia Vera
Authors: Dzhariyat Shikhbabaeva, Vasily Shuvaev, Sergey Kapustin, Irina Martynkevich, Vera Udaleva, Regina Golovchenko, Tatyana Zamotina, Mikhail Fominykh, Irina Zotova, Lyubov Polushkina, Kudrat Abdulkadyrov
Journal: Blood (2015)
Experience with Fludarabine, Cyclophosphamide, Rituximab (FCR) Plus GM-CSF in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL)
Authors: Alessandra Ferrajoli, Stefan Faderl, Susan O’Brien, William Wierda, Ana Ayala, Susan Smith, Tiffany C Brown, Hagop Kantarjian, Michael Keating
Journal: Blood (2008)
AB0807 Gout in Rural Area in Sub-Saharan Africa: A Comparison between Patients Coming from Rural and Urban Areas, in An Urban Tertiary Healthcare Center in Cameroon: Table 1.
Authors: F. Kemta Lekpa, M.S. Doualla, M. Singwe-Ngandeu, H. Namme Luma
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout, the disease of kings is seen today in both urban and rural areas. However, few data are available on the characteristics of gout in the rural area, especially in sub-Saharan Africa. <h3>Objectives</h3> To evaluate the differences between gouty patients in rural and urban areas in Cameroon, Central Africa. <h3>Methods</h3> We performed a cross-sectional study in all 511 patients (96 women and 415 men) seen at General Hospital, Douala, Cameroon, between January 2004 and December 2013. The main demographic and clinical features of gouty patients living in rural and urban were compared. A <i>p</i>&lt; 0.05 was considered statistically significant. <h3>Results</h3> The baseline characteristics of patients are presented in Table 1. Patients living in rural areas were older, had an oligoarticular clinical presentation, more hyperuricemia and higher serum uric acid levels and a more frequent chronic inflammation compared to patients living in urban areas. Chronic kidney disease and dyslipidemia were more frequent in rural areas while obesity and hypertension were more frequent in urban areas. <h3>Conclusions</h3> Gout is characterized in patients living in rural area by a late age at onset and hyperuricemia higher compared to patients living in urban area. Cardiovascular risk factors are common. Further studies are needed to evaluate lifestyle changes in rural area. <h3>Disclosure of Interest</h3> None declared
Management and Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Retrospective Study By the Lymphoma Study Association
Authors: Julien Lazarovici, Pauline Brice, Lucie Obéric, Isabelle Gaillard, Mathilde Hunault-Berger, Florence Broussais, Serge Bologna, Emmanuel Gyan, Catherine Sebban, Mohamed Touati, Richard Delarue, Frédérique Orsini-Piocelle, Aspasia Stamatoullas, Peggy Dartigues, Marc PE André, Olivier Casasnovas, Nicolas Mounier, Christophe Fermé
Journal: Blood (2014)
Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)
Authors: Sebastian Boettcher, Matthias Ritgen, Kirsten Fischer, Stephan Stilgenbauer, Raymonde Busch, Gunter R. Fingerle-Rowson, Anna-Maria Fink, Andreas Buehler, Dirk Winkler, Michael K. Wenger, Myriam Mendila, Clemens Wendtner, Barbara Eichhorst, Hartmut Döhner, Michael Hallek, Michael Kneba
Journal: Blood (2011)
Babies with microcephaly in Brazil are struggling to access care
Authors: Cláudia Collucci
Journal: BMJ (2016)

One year after the Brazilian Ministry of Health declared a public health emergency because of the large rise in the number of children born with microcephaly, those children are experiencing difficulties in accessing care.

The first of these children are now a year old, but most cannot crawl, walk, sit unaided, or hold objects. Many have severe visual and hearing deficiencies and malformations in the legs and arms. Most take painkillers to control irritation and repeated crying, and receive treatment for seizures.

By the end of October Brazil had 2106 confirmed cases of congenital Zika virus syndrome. Another 3091 cases remain under investigation.1 Around 80% of cases are concentrated in the north east of the country. The BMJ spoke to families of babies with the syndrome in the two north eastern states of Paraiba and Pernambuco and to the clinicians treating them. …
THU0568 Ultrasonography of Salivary Glands for Diagnose of IGG4-Related Mikulicz's Disease
Authors: D.F. Lin, W.Q. Yang, M.J. Zhao, J.Y. Cao, Z.T. Liao
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Immunoglobulin 4-related Mikulicz9sdisease (IgG4-MD) is a subtype of IgG4-related diseases with the future of swollen bilateral salivary glands and highly responsive to gluccocorticoids (GCs) therapy. It has the similar ultrasonography (US) features as primary sjogren9s syndrome (pSS) including multiply hypoechoic zone, hyperechogenic reflections, inhomogeity and echogeneity appearance of the parotid and submandibular glands. Our study tried to distinct IgG4-MD from pSS by US. <h3>Objectives</h3> Our study tried to distinct IgG4-MD from pSS by US. <h3>Methods</h3> 7 cases of IgG4-MD with parotid involvement and 28 cases of pSS first diagnosed without treatment before were observed by ultrasonography (US) of bilateral parotid and submandibular glands. Parameters includes parotid gland depth, submandibular size were recorded, and the extent of nodal hypoechoic areas, hyperchogenic reflections, inhomogeity, echogeneity, border clearness were scored according to the pSS US scoring system designed by Hocevar. Afterward, 7 IgG4-MD and 28 pSS patients were given 16mg Methylprednisolone and then tapered 4mg per month and followed up by US after 3 months. <h3>Results</h3> 1) The parotid gland depth of IgG4-MD were significantly larger than of pSS (38±7mm: 11±5mm, p&lt;0.01). 2) The scores of hypoechoic areas, hyperchogenic reflections, inhomogeity of IgG4-MD cases by Hocevar9s method were significantly higher than of pSS cases repectively (mean scores=9.1: 6.3, 11.1: 3.6, 11.8: 5.9, p&lt;0.01), border clearness and echogeneity were not significantly difference. 3) It is shown depth of bilateral parotid glands (38±7mm: 14±3mm) and the score of hypoechoic areas (9.1: 3.7, p&lt;0.01) in IgG4-MD cases remarkably decreased after 3 month follow-up, however, no too much difference of the depth of bilateral parotid glands (11±5mm: 10±6mm) and the score of hypoechoic areas (6.3: 5.3) in pSS cases. <h3>Conclusions</h3> Ultrasound could be used for distinguish IgG4-MD salivary involvement from pSS for monitoring the depth of parotid and scoring hypoechoic areas especially during the GCs therapy. <h3>Disclosure of Interest</h3> None declared
PTU-103 How Best to Deliver Enteral Access for Post-Pyloric Home Enteral Tube Feeding? A 2-Year Review
Authors: N Gautam, HM Htet, Y Smith, NC Fisher
Journal: Gut (2016)

<h3>Introduction</h3> Home enteral tube feeding (HETF) has grown in the past 2 decades and there is now also a growing demand for post-pyloric HETF (PP-HETF) for selected cases.<sup>1,2</sup> The optimum route for delivering this is not established, with several options available including surgical jejunostomy (SJ), direct percutaneous endoscopic jejunostomy (DPEJ), and PEG with jejunal extension (PEG-J). We have reviewed our experience to help identify comparative outcomes. <h3>Methods</h3> Choice of feeding device was clinician-led according to indication, surgical and endoscopic risk. A 2 year review was done from Jan 2014 onwards. Patients were included if they were (1) already undergoing PP-HETF as of January 2014 or (2) had an interventional procedure to start PP-HETF at any time thereafter during the study period. Cases were identified from the community dietetic and electronic endoscopy databases. Case files were reviewed to identify outcome measures which were categorised as: Success of planned procedures; longevity of feeding device, premature removal (removal because of sepsis, migration, blockage or accidental), procedural complications or mortality <h3>Results</h3> 26 patients were identified (M:F 14:12, median age 55, range 22–83). Indications for PP-HETF were learning difficulties with Gastro-oesophgeal(GO) reflux (8), neurodegenerative or cerebrovascular disease with GO reflux (5), upper GI cancers(9) &amp; others (4). Feeding interventions done successfully prior to or during the study period were SJ (10), DPEJ (14), PEG-J (14).Procedural success rates during study period were; SJ; 10/10 (100%), DPEJ;7/11 (64%), PEG-J; 12/13 (92%).Longevity of feeding devices at review census point (in months, median &amp; range) was: SJ, 11 (3–23); DPEJ,18 (3–48); PEG-J, 6 (0.25–23). Tube premature removal rates (and reasons) were: SJ; 3/10 (30%; all fell out), DPEJ; 3/14(21%; 1 accidental, 2 infected), PEG-J; 6/14 (43%; 4 accidental, 2 blocked). There were no procedural complications recorded but one patient (DPEJ) died &lt;7 days from respiratory failure. <h3>Conclusion</h3> In this case series which includes similar numbers of the common PP-HETF options, SJ had the highest, and DPEJ the lowest, procedure success rate.DPEJ had the highest longevity. Choice of feeding device for PP-HETF will depend on co-morbidity and surgical/ endoscopic risk but when DPEJ can be placed this may be the preferred option for long-term feeding. <h3>References</h3> 1 Ojo O. Managing patients on enteral feeding tubes in the community. <i>Br J Community Nurs</i> 2010;<b>15</b>:S6–S13. 2 Ojo O. The challenges of home enteral tube feeding: a global perspective. <i>Nutrients</i> 2015;<b>7</b>(4):2524–2538. doi:10.3390/nu7042524. <h3>Disclosure of Interest</h3> None Declared
Human Herpes Virus 6 Infection in 54 Patients after Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Manifestations and Outcome
Authors: Raffaella Greco, Lara Crucitti, Sara Racca, Roee Dvir, Francesca Lorentino, Luca Vago, Alessandra Forcina, Serena Rolla, Veronica Valtolina, Maddalena Noviello, Maria Teresa Lupo Stanghellini, Fabio Giglio, Mara Morelli, Giorgia Levati, Andrea Assanelli, Matteo G Carrabba, Sarah Marktel, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Chiara Bonini, Massimo Clementi, Fabio Ciceri
Journal: Blood (2014)
Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling
Authors: Jarno Kivioja, Mika Kontro, Angeliki Thanasopoulou, Muntasir Mamun Majumder, Bhagwan Yadav, Heikki Kuusanmäki, Alun Parsons, Juerg Schwaller, Kimmo Porkka, Caroline A Heckman
Journal: Blood (2014)
PWE-007 Liver Disease in Patients with Inflammatory Bowel Disease (IBD): Causes, Presentations and Outcomes: Abstract PWE-007 Table 1
Authors: BD Warner, M Basra, S Anderson, P Irving, J Sanderson
Journal: Gut (2016)

<h3>Introduction</h3> Although deranged liver function tests(LFTs) are seen in around 1/3 of patients with IBD at some point during the course of their disease,there is a lack of clarity over how this should be investigated and managed. <h3>Methods</h3> IBD patients attending clinic between September 2014 and December 2015 were analysed for previously elevated alanine transferase((ALT) defined as &gt;56 IU/L). Analyses,where there were derangement of gamma glutamyl transferase and alkaline phosphatase (ALP) only,were not performed. Data was collected for disease activity,medication,time to ALT normalisation(in months) and ALP. <h3>Results</h3> Data on 236 patients with elevated ALT were collected(50.4% male, mean age 40 years(range 16 to 83)). 64% had Crohn’s disease(CD). 61% had active disease at the time of elevated ALT. Liver injury was predominantly hepatitic(mean ALT:ALP ratio 1.52). Mean ALT was 159 (maximum 1980). Of the patients with PSC,81% had ulcerative colitis(UC) of whom 75% had pancolitis. The mean ALT:ALP ratio was 0.47 and therefore cholestatic(SD 0.29). Overall,70% of patients had an ALT which normalised completely(mean of 2.4 months(SD 2.7)). 37% were due to thiopurines and 35% due to disease flares. 6% were other drug related (methotrexate in 8 cases, mesalazines in 2). Where ALT did not normalise,21% were diagnosed with a chronic liver disease. 2/3 of thiopurine-induced hepatotoxicity were associated with hypermethylation(Methylmercaptopurine to thioguanine nucleotide ratio &gt;11) and mean ALT:ALP was 1.74 and therefore hepatitic(range 0.15–11.57,SD 1.67). Median time for normalisation of thiopurine-induced hepatotoxicity was 2 months(SD 3.9) where as it was 0.5 months(SD 15.5) due to flares. <h3>Conclusion</h3> Liver disease in IBD is common but rarely severe. Thiopurines are the commonest cause. Liver injury associated with active disease is also common. ALT normalised completely in over 95% of drug related cases. Where deranged LFTs continue for over 2 months,then a liver screen is indicated to exclude a chronic liver disease. Where liver derangement is cholestatic and the patient has UC, investigations should be carried out to exclude PSC. <h3>Disclosure of Interest</h3> None Declared
PTH-060 Better Care for IBD Biologic Patients: The Impact of A Multi-Disciplinary Virtual Clinic
Authors: E Eliadou, V Reid, M Kirkbride, J Brooks, F Birchall, K Kemp, S Levison
Journal: Gut (2016)

<h3>Introduction</h3> The IBD Standards, the Royal College of Physicians national biologic audit, and the NICE IBD quality standard (QS81) all aim to help deliver high quality, safe and appropriate clinical care to IBD patients throughout the UK. In line with these recommendations, and to improve and standardise the care of our IBD patients on biologic therapies we began a weekly multi-disciplinary (physicians, IBD nurses, and pharmacist) virtual biologics clinic (VBC). Here, the response to therapy is monitored (clinical scoring, well-being, laboratory results), the scheduling of investigations are coordinated, and the review and writing of prescriptions undertaken. <h3>Methods</h3> We prospectively collected data from our VBC for 8 consecutive weeks. Changes to therapy on clinical grounds were noted, and the financial implications of these changes calculated. Calculations for IFX savings were based on an average dose of 300 mg per patient, plus infusion costs. The ordering of required investigations and the occurrence of adverse clinical events were recorded <h3>Results</h3> In 8 weeks, 360 patient reviews were performed relating to 327 patients (IFX = 207, ADA = 79, VEDO = 41). Therapy was adjusted in 41/327 patients (12.5%). 5 stopped biologic therapy, 19 switched drug, 10 reduced and 7 increased the frequency of therapy. Net saving was £10,928 at week 8 (&gt;£65 K/annum). The coordinated prescribing of medication and pharmacy sign off improved the delivery of therapy and patient satisfaction. 23 colonoscopies, 9 MR scans, and 45 outpatient appointments to assess response to therapy at 3 or 12 months and clinical input were scheduled from the VBC. The ordering of anti-TNF drug and antibody levels solely through the VBC reduced any duplication of requests and ensured the review and actioning of results. 5 complications were highlighted (recurrent infections; 2 requiring surgery; cancer; severe IBD flare requiring hospitalisation). <h3>Conclusion</h3> The introduction of a multi-disciplinary VBC has altered the management of 41/327 patients (12.5%) based on clinical findings and the results of investigations. Significant financial savings (£65 K per annum), the streamlining of prescribing, and superior patient monitoring have helped to improve the quality and safety of care provided. With better monitoring, care, NICE compliance, and financial prudence, this will help to sustain or service and practices. <h3>Disclosure of Interest</h3> None Declared
VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network
Authors: Brad Kahl, Julie Chang, Jens Eickhoff, Leslie Gilbert, Eric Rogers, Jae Werndli, Michael Huie, Thomas McFarland, Michael Volk, Jules H. Blank, Natalie Callander, Walter Longo, Christopher Peterson
Journal: Blood (2008)
The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk
Authors: Kimberly H. Harrington, Chelsea J. Gudgeon, George S. Laszlo, Kathryn J. Newhall, Angus M. Sinclair, Stanley R. Frankel, Roman Kischel, Guang Chen, Roland B. Walter
Journal: Blood (2014)
Correlation of Altered Expression of RIZ1 to Diagnosis, Risk Stratification, and Disease Progression in 56 Acute Leukemia Patients.
Authors: Qiubai Li, Xiaojian Zhu, Xiaoqing Li, Xiangjun Chen, Yong You, Shi Huang, Shiang Huang, Ping Zou, Zhichao Chen
Journal: Blood (2009)
Tositumomab and Iodine I-131 Tositumomab (Bexxar® therapeutic regimen) for Non-Hodgkin's Lymphoma Patients Who Progressed After Treatment with Rituximab: Long Term Follow-up of a Multi-Center Phase II Study.
Authors: Sandra J Horning, Anas Younes, Donald Podoloff, Thierry J Horner, Vanessa C Williams, Christina Vleisides, Michael Goris
Journal: Blood (2009)
Tumoral Maximum Standardized Uptake Value &gt; 10 Measured on 18 f-FDG-PET: A New Valid Marker to Discriminate Richter Syndrome
Authors: Anne-Sophie Michallet, Pierre P Sesques, Kari G. Rabe, Jeremy Tordot, Christelle Tychyj-Pinel, Baseggio Lucile, Gilles Salles, Jehan Dupuis, Michael J. Conte
Journal: Blood (2014)
THU0279 Mscs Alleviate Clinical and Experimental Sjogren's Syndrome by Inhibiting IL-12 Production of APCS
Authors: B. Shi, J. Qi, R. Feng, Z. Zhang, W. Chen, W. Li, X. Tang, G. Yao, L. Sun
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Mesenchymal stem cells (MSCs) have been demonstrated to be effective in treating clinical and experimental Sjogren9s syndrome (SS). However, the underlying mechanisms of benefit effects of MSCs on pSS remain unclear. IL-12 was mainly generated from monocytes, dendritic cells (DCs) and macrophages, and regarded as a pro-inflammatory cytokine in autoimmune diseases, including SS. <h3>Objectives</h3> In this study we test whether the therapeutic effects of MSCs on SS is mediated by reducing IL-12 production. <h3>Methods</h3> 1×10<sup>6</sup> human umbilical cord derived MSCs were injected into NOD mice (experimental Sjogren9s syndrome, ESS) via tail vein. 4 weeks later, the salivary flow rates were detected. Splenocytes were collected and CD11c+ and CD11b+ cells were sorted by magnetic beads. Lacrimal and salivary glands were collected for histologic analysis. Serum IL-12 was quantified by ELISA inprimary Sjogren9s syndrome (pSS) patients and healthy controls. 5 patients with pSS received MSCs transplantations. Whole blood was collected before MSCs treatment and 4 weeks later. CD14+ cells from pSS patients and healthy controls were isolated by magnetic beads. The CD14+ cells were induced to generate DCs or macrophages. Expression of IL-12 was detected by RT-PCR. Human THP-1 cells were induced towards macrophage or DC. THP-1 cells, THP-1-induced macrophages and DCs were co-cultured with MSCs, respectively. IL-12 levels in supernatants were detected by ELISA. IL-12 gene expression was quantified by real-time PCR. <h3>Results</h3> MSCs transplantation improved salivary flow rates and decreased lymphocyte infiltrations in lacrimal and salivary glands, proving its effectiveness in alleviating symptoms of NOD mice. <i>In vivo</i> transplantation of MSCs into NOD mice also reduced serum IL-12 levels, and IL-12 mRNA in CD11c+ and CD11b+ cells. Serum IL-12 levels were significantly increased in pSS patients. MSCs transplantation also decreased IL-12 levels in pSS patients after 4 weeks. CD14+ monocytes, monocyte-derived DCs and macrophages from pSS patients generated significantly more IL-12 than that from healthy individuals. MSCs significantly reduced IL-12 production by human THP-1-induced DCs, macrophages or monocytes <i>in vitro</i>. Moreover, MSCs also decreased IL-12 production in mouse Raw246.7 cells (mouse macrophage), mouse CD11c+ cells and CD11b+ cells <i>in vitro</i>. <h3>Conclusions</h3> IL-12 over-production by APCs may contribute to the pathogenesis of pSS and ESS. MSCs may alleviate clinical and experimental Sjogren9s syndrome through decreasing IL-12 production. <h3>Disclosure of Interest</h3> None declared